Abstract 556P
Background
Iruplinalkib (WX-0593) is a novel ALK TKI. Here, we report the results from the phase 1 study on efficacy and safety of iruplinalkib for ALK-positive NSCLC patients who received prior second-generation ALK TKIs.
Methods
ALK- or ROS1-positive advanced NSCLC patients were enrolled in the phase 1 study. In the dose-escalation phase, patients received iruplinalkib 30–300 mg orally once daily. In the dose-expansion phase, patients received iruplinalkib 120 or 180 mg orally once daily with or without a 7-day lead-in at 60 mg. Efficacy and safety were assessed by investigators. ALK-positive patients previously treated with second-generation ALK TKIs were included in this analysis.
Results
Totally, 153 patients were enrolled in the phase 1 study, among which 11 patients (five [45%] in the dose-escalation phase and six [55%] in the dose-expansion phase) who received prior second-generation ALK TKIs were eligible for this analysis. Median age was 52 years old. Six (55%) were male. There were one (9%), four (36%), four (36%) and two (18%) patients in 90 mg, 120 mg, 180 mg, and 240 mg orally once daily group of iruplinalkib, respectively. Brain metastasis and prior treatment were summarized in the table. As of the data cut-off date on July 31, 2023, median follow-up was 53.3 months. Six patients (55%, 95% confidence interval [CI] 23%–84%) had objective response. Median progression-free survival (PFS) was 8.1 months (95% CI 2.2–30.2). Nine (82%) and three (27%) patients experienced any grade and grade ≥ 3 treatment-related adverse event (TRAE), respectively. Other endpoints were shown in the table. Table: 556P
Parameters | Results (n=11) |
Baseline brain metastasis | 7 (64%) |
Prior ALK TKIs | |
Crizotinib + second-generation | 9 (82%) |
Second-generation only | 2 (18%) |
Detailed second-generation ALK TKI | |
Ensartinib | 5 (45%) |
Conteltinib | 4 (36%) |
Ceritinib | 1 (9%) |
Brigatinib | 1 (9%) |
Prior chemotherapy | 9 (82%) |
Best objective response | |
Partial response | 6 (55%) |
Stable disease | 4 (36%) |
Progressive disease | 1 (9%) |
Objective response | 6 (55%, 95% CI 23%–83%) |
Disease control | 10 (91%, 95% CI 59%–100%) |
PFS event | 9 (82%) |
Median PFS, months | 8.1 (95% CI 2.2–30.2) |
Any grade TRAE | 9 (82%) |
Grade ≥ 3 TRAE | 3 (27%) |
TRAE leading to dose interruption/reduction/discontinuation | 2 (18%)/0/0 |
Conclusions
Iruplinalkib demonstrated promising efficacy and acceptable toxicity in ALK-positive advanced NSCLC patients previously treated with second-generation ALK TKIs.
Clinical trial identification
NCT03389815.
Editorial acknowledgement
We thank Yunjie Yu (Qilu Pharmaceutical Co., Ltd., Jinan, China) for providing medical writing support.
Legal entity responsible for the study
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs.
Funding
Qilu Pharmaceutical Co., Ltd. (Jinan, China) and China National Major Project for New Drug Innovation (2017ZX09304015).
Disclosure
M. Wang, M. Si, Y. Sang, X. Kang: Financial Interests, Personal, Full or part-time Employment: Qilu Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract